CA2952159C - Method of screening of compounds using membrane stim1 - Google Patents

Method of screening of compounds using membrane stim1 Download PDF

Info

Publication number
CA2952159C
CA2952159C CA2952159A CA2952159A CA2952159C CA 2952159 C CA2952159 C CA 2952159C CA 2952159 A CA2952159 A CA 2952159A CA 2952159 A CA2952159 A CA 2952159A CA 2952159 C CA2952159 C CA 2952159C
Authority
CA
Canada
Prior art keywords
cells
stim1
screening
plasma membrane
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2952159A
Other languages
English (en)
French (fr)
Other versions
CA2952159A1 (en
Inventor
Yves Renaudineau
Olivier Mignen
Miguel Burgos
Jacques Olivier Pers
Tinhinane Fali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Regional et Universitaire de Brest
Univerdite de Bretagne Occidentale
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Regional et Universitaire de Brest
Univerdite de Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Regional et Universitaire de Brest, Univerdite de Bretagne Occidentale filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of CA2952159A1 publication Critical patent/CA2952159A1/en
Application granted granted Critical
Publication of CA2952159C publication Critical patent/CA2952159C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/57505—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2952159A 2014-08-06 2015-07-31 Method of screening of compounds using membrane stim1 Active CA2952159C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14290232.9A EP2982982B1 (en) 2014-08-06 2014-08-06 Method of screening of compounds using membrane STIM1
EP14290232.9 2014-08-06
PCT/EP2015/067615 WO2016020274A1 (en) 2014-08-06 2015-07-31 Method of screening of compounds using membrane stim1

Publications (2)

Publication Number Publication Date
CA2952159A1 CA2952159A1 (en) 2016-02-11
CA2952159C true CA2952159C (en) 2022-08-30

Family

ID=51398585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2952159A Active CA2952159C (en) 2014-08-06 2015-07-31 Method of screening of compounds using membrane stim1

Country Status (11)

Country Link
US (2) US20170219588A1 (enExample)
EP (2) EP2982982B1 (enExample)
JP (2) JP6754751B2 (enExample)
CN (2) CN110051836B (enExample)
CA (1) CA2952159C (enExample)
DK (1) DK2982982T3 (enExample)
ES (1) ES2654674T3 (enExample)
NO (1) NO2982982T3 (enExample)
PL (1) PL2982982T3 (enExample)
PT (1) PT2982982T (enExample)
WO (1) WO2016020274A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714943A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3715848A1 (en) * 2019-03-25 2020-09-30 Université de Bretagne Occidentale (U.B.O.) Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods
EP3714942A1 (en) * 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
US20240083990A1 (en) * 2021-01-26 2024-03-14 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341484T3 (es) * 2005-05-20 2010-06-21 Genentech, Inc. Pretratamiento de una muestra biologica de un sujeto que sufre una enfermedad autoinmune.
WO2008148108A1 (en) * 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
EP2472262A3 (en) * 2007-07-10 2012-10-17 Immune Disease Institute, Inc. Stromal interacting molecule knockout mouse and uses thereof
WO2009021338A1 (en) * 2007-08-15 2009-02-19 UNIVERSITé DE SHERBROOKE Alternative splicing gene variants in cancer detection
AU2008299220B2 (en) * 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2103311A1 (en) * 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
WO2010099401A1 (en) * 2009-02-26 2010-09-02 The Board Of Trustees Of The Leland Stanford Junior University Calcium signaling modulators involving stim and orai proteins
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US20160194393A1 (en) * 2011-08-10 2016-07-07 Biommune Technologies Inc. Methods and compositions for modulating voltage-gated calcium channel function
CN102433383B (zh) * 2011-12-19 2015-07-08 上海吉凯基因化学技术有限公司 人stim1基因的用途及其相关药物

Also Published As

Publication number Publication date
NO2982982T3 (enExample) 2018-03-03
PT2982982T (pt) 2018-01-03
JP2019214576A (ja) 2019-12-19
JP6861246B2 (ja) 2021-04-21
CA2952159A1 (en) 2016-02-11
PL2982982T3 (pl) 2018-03-30
EP3177929A1 (en) 2017-06-14
US20170219588A1 (en) 2017-08-03
JP6754751B2 (ja) 2020-09-16
JP2017531164A (ja) 2017-10-19
EP2982982B1 (en) 2017-10-04
CN110051836A (zh) 2019-07-26
ES2654674T3 (es) 2018-02-14
CN106716130B (zh) 2019-03-29
EP2982982A1 (en) 2016-02-10
US20190154690A1 (en) 2019-05-23
DK2982982T3 (en) 2018-01-08
WO2016020274A1 (en) 2016-02-11
CN110051836B (zh) 2023-05-26
EP3177929B1 (en) 2018-05-09
CN106716130A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
Gauvain et al. The neuronal K-Cl cotransporter KCC2 influences postsynaptic AMPA receptor content and lateral diffusion in dendritic spines
Xavier et al. Membrane compartmentation is required for efficient T cell activation
Tarkowski et al. Resistin competes with lipopolysaccharide for binding to toll‐like receptor 4
Chae et al. Cross-talk between RhoH and Rac1 in regulation of actin cytoskeleton and chemotaxis of hematopoietic progenitor cells
O’Brien et al. Role of immunoreceptor tyrosine-based inhibitory motifs of PECAM-1 in PECAM-1-dependent cell migration
US20190154690A1 (en) Method of treating chronic lymphatic leukaemia and/or systemic lupus erythematosus
Holland et al. LYST affects lysosome size and quantity, but not trafficking or degradation through autophagy or endocytosis
Bai et al. Role of acid sphingomyelinase bioactivity in human CD4+ T-cell activation and immune responses
Huang et al. Activation of adhesion GPCR EMR2/ADGRE2 induces macrophage differentiation and inflammatory responses via Gα16/Akt/MAPK/NF-κB signaling pathways
Guidetti et al. The small proteoglycan decorin supports adhesion and activation of human platelets
Capuano et al. PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway
Kacena et al. Megakaryocytes regulate expression of Pyk2 isoforms and caspase-mediated cleavage of actin in osteoblasts
Yaroslavskiy et al. NO-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and VASP
An et al. Soluble LILRA3 promotes neurite outgrowth and synapses formation through a high-affinity interaction with Nogo 66
Fu et al. The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
Purdy et al. SHP-2 expression negatively regulates NK cell function
Schmid et al. PI3Kγ stimulates a high molecular weight form of myosin light chain kinase to promote myeloid cell adhesion and tumor inflammation
Marrone et al. Alternative splicing of FKBP5 gene exerts control over T lymphocyte expansion
Fontanella et al. CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells
Micucci et al. PI5KI-dependent signals are critical regulators of the cytolytic secretory pathway
Pye et al. Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy
Chung et al. Inhibition of T‐cell activation by syndecan‐4 is mediated by CD148 through protein tyrosine phosphatase activity
Jevnikar et al. Cathepsin X cleaves the β2 cytoplasmic tail of LFA‐1 inducing the intermediate affinity form of LFA‐1 and α‐actinin‐1 binding
Bastian et al. Phosphatidylinositol 3-Kinase in the G Protein-Coupled Receptor–Induced Chemokinesis and Chemotaxis of MDA-MB-468 Breast Carcinoma Cells: A Comparison with Leukocytes
Arabanian et al. Regulation of fas/fas ligand‐mediated apoptosis by nuclear factor of activated T cells in megakaryocytes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200429

EEER Examination request

Effective date: 20200429

EEER Examination request

Effective date: 20200429